Oct 15, 2024 | Benefits preservation, Biosimilar, Claims, Cost Savings, Drug costs, Rx Costs, Savings, Specialty Drugs
Specialty drugs continue to drive up pharmacy costs, accounting for over 50% of total drug spend for many self-funded health plans, despite being used by a small percentage of patients. But pharmaceutical and administrative solutions are available to help reduce that...
Sep 3, 2024 | Biosimilar, Drug costs, GLP-1s, Humira, Mounjaro, Ozempic, Rx Costs, Stelara, Trulicity, Wegovy
Humira continued to be the costliest prescription drug for self-funded health plans in 2023 by a comfortable margin, according to a recent Milliman commercial drug trends review. Used to treat a variety of conditions from Crohn’s to rheumatoid arthritis and psoriatic...
Aug 5, 2024 | Biosimilar, Cost Savings, Food and Drug Administration (FDA), Humalog, Opinions, Savings
From a STAT opinion piece by Juliana M. Reed, executive director of the Biosimilars Forum: “Biologic medicines are some of the most important drugs in the world. They are also among the most expensive. Biosimilars are FDA-approved treatments that are similar to...
Jul 5, 2024 | Biosimilar, Cost Savings, Drug costs, Humira, Idacio, MedBen Rx, News, Rx Costs, Savings
The Food and Drug Administration is considering a change to its biosimilar policy that would greatly speed up their approval process – which, if enacted, would be a big win for MedBen Rx clients who are already reducing their prescription drug spend through...
Apr 16, 2024 | Biosimilar, Cost Savings, Drug costs, Humira, Idacio, Prescription drugs, Rx Costs, Savings
Last year, MedBen Rx announced a new program that would enable clients to purchase Idacio, a biosimilar version of the anti-inflammatory therapy Humira – a drug that typically costs between $6,000 and $12,000 per month depending on the dose – for under $1,000 per...
Sep 29, 2023 | Announcements, Biosimilar, Humira, MedBen Rx, News, Perigon Pharmacy 360, Ventegra
Here’s some cost-saving news for MedBen Rx clients who use Ventegra as their processor. On July 1, 2023, biosimilar products were released for the popular and expensive anti-inflammatory therapy, Humira. A 30-day supply of Humira, which is used to treat a variety of...
